Protein Tyrosine Phosphatase-Like A Regulates Myoblast Proliferation and Differentiation through MyoG and the Cell Cycling Signaling Pathway by Xi Lin et al.
Protein Tyrosine Phosphatase-Like A Regulates Myoblast Proliferation
and Differentiation through MyoG and the Cell Cycling
Signaling Pathway
Xi Lin,a Xiangsheng Yang,a Qi Li,b Yanlin Ma,b Shuang Cui,c Dacheng He,c Xia Lin,d Robert J. Schwartz,e and Jiang Changa,b
Texas A&M Health Science Center, Institute of Biosciences and Technology, Houston, Texas, USAa; Hainan Provincial Key Laboratory for Human Reproductive Medicine
and Genetic Research, Affiliated Hospital of Hainan Medical College, Hainan, Chinab; Beijing Normal University, Beijing, Chinac; Surgery/General Surgery Division, Baylor
College of Medicine, Houston, Texas, USAd; and Biology and Biochemistry Department, University of Houston, Houston, Texas, USAe
Protein tyrosine phosphatase-like A (PTPLa) has been implicated in skeletal myogenesis and cardiogenesis. Mutations in PTPLa
correlated with arrhythmogenic right ventricular dysplasia in humans and congenital centronuclear myopathy with severe hy-
potonia in dogs. The molecular mechanisms of PTPLa in myogenesis are unknown. In this report, we demonstrate that PTPLa is
required for myoblast growth and differentiation. The cells lacking PTPLa remained immature and failed to differentiate into
maturemyotubes. The repressedMyoG expressionwas responsible for the impairedmyoblast differentiation.Meanwhile, impeded
cell growth,with an obvious S-phase arrest and compromisedG2/M transition, was observed in PTPLa-deficientmyoblasts. Further
study demonstrated that the upregulation of cyclinD1 and cyclin E2 complexes, alongwith a compromisedG2/M transition due to the
decreasedCDK1 (cyclin-dependent kinase 1) activity andupregulated p21, contributed to themutant cell S-phase arrest and eventually
led to the retarded cell growth. Finally, the transcriptional regulation of the PTPLa genewas explored.We identifiedPTPLa as a new
target gene of the serum response factor (SRF). Skeletal- and cardiac-muscle-specific SRF knockouts resulted in significant decreases in
PTPLa expression, suggesting a conserved transcriptional regulation of the PTPLa gene inmice.
Skeletalmyogenesis involvesmultiple processes inwhich undif-ferentiatedmyoblasts proliferate, withdraw from the cell cycle,
and differentiate intomononucleatedmyocytes followed by a sub-
sequent fusion of myocytes into multinucleated myotubes. The
latter are assembled into mature muscle fibers along with the ex-
pression of muscle-specific proteins. The multistep process is
tightly regulated in order to secure normal myogenesis develop-
ment. Extensive studies that have focused onmyogenic transcrip-
tional regulation revealed four essential myogenic regulatory
factors (MRFs), MyoD (17), MyoG (myogenin) (20, 65), Myf5
(muscle regulatory factor 5) (11), and MRF4 (muscle regulatory
factor 4) (10, 47, 55). These factors function coordinately at
different stages of muscle cell fate during development and play
crucial roles in myogenesis. In comparison with myogenic tran-
scriptional regulation, there have been far fewer studies of post-
translational regulation of myogenesis. Accumulating evidence
has begun to reveal that tyrosyl phosphorylation and its opposite,
dephosphorylation, are important regulatory components during
myogenic progression. Several representative studies have exam-
ined focal adhesion kinase (FAK), a nonreceptor tyrosine kinase
also known as protein tyrosine kinase 2 (53, 54), phosphatidylino-
sitol 3=-kinase (PI3K) (16, 30), phosphoinositide phosphatase
myotubularin, and protein tyrosine phosphatase SHP-2 (22,
32, 33).
Protein tyrosine phosphatase-like A (PTPLa) is a protein ty-
rosine phosphatase in which the active motif (I/V)HCXXGXXP
(S/T) contains an arginine-to-proline replacement (indicated by
boldface) (61). While the significance of this substitution remains
to be determined, the developmental expression and specific tis-
sue distribution of the mouse PTPLa transcripts strongly imply a
role in skeletal myogenesis and cardiogenesis. In mouse embryos,
PTPLa expression in somites throughout myogenesis and in car-
diomyocytes of the primitive heart was detected by in situ hybrid-
ization as early as embryonic day 8.5 (E8.5) (61). Consistent with
the embryonic expression pattern, the highest transcript levels of
PTPLa were observed in adult mouse heart and skeletal muscle
(61). However, the biological function of PTPLa in muscle devel-
opment remains largely unknown. Mutations in the PTPLa gene
were found in patients suffering from arrhythmogenic right ven-
tricular dysplasia (ARVD) (31, 38) and in Labrador retrievers suf-
fering from congenital myopathy (52), suggesting a potential role
of PTPLa in muscle development and normal function.
In this study, we assessed PTPLa protein levels in adult mouse
tissues and found that PTPLa was almost exclusively expressed in
heart and skeletalmuscle.We then usedC2C12myoblasts as a tool
to study PTPLa’s effect on myoblast proliferation and differenti-
ation and the associated molecular mechanism by gain- and loss-
of-function approaches. Our data provide evidence that PTPLa is
an important regulator in skeletal myogenesis. The promyogenic
role of PTPLa is associated with the modulation of myogenic dif-
ferentiation and proliferation, and PTPLa deficiency impedes
both processes. Furthermore, we explored PTPLa transcriptional
regulation and identified SRF (serum response factor) as a major
transcription factor responsible for PTPLa gene expression.
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MATERIALS AND METHODS
Cell culture and plasmid constructs. C2C12 mouse myoblasts were cul-
tured in either growth medium (GM) or differentiation medium (DM).
The GM, which consisted of Dulbecco’s modified Eagle’s medium
(DMEM) and 20% fetal bovine serum (FBS), was used to grow the C2C12
myoblasts and keep them from differentiation. For differentiation exper-
iments, the cells were cultured in DM that contained DMEM and 2%
heat-inactivated horse serum. Cell synchronization at G0 was achieved by
culturing cells in 1%FBS for 24 h. For double-thymidine synchronization,
cells were treated with 1 mM thymidine for 12 h followed by a 10-h break
and were then treated again with the same dose of thymidine for another
12 h before the blockage release.
The mouse PTPLa cDNA was cloned from a wild-type C57 mouse
heart cDNA template by PCR. The PCR primers designed based on the
mouse PTPLa mRNA sequence (NCBI accession no. NM_013935)
were 5=-ATGCCGCTCGAGCTCCTGTGCGCTGCTCCT-3= (forward)
and 5=-ATGCCGGAATTCGCACCTTGTGTGTGGGAAC-3= (reverse).
The PTPLa cDNA was cloned into the pcDNA3.1/myc-his() B (Invit-
rogen) with a green fluorescent protein (GFP) tag at the C terminus. SRF
expression vector was generated as previously described (14). The human
MyoG-expressing plasmid was from OriGene.
Generation of PTPLa and MyoG-deficient myoblast cell lines. Len-
tiviral vectors V2LHS_5923, and V2LMM_6871 (Thermo Scientific) ex-
pressing short hairpin RNAs (shRNAs) specific for mouse PTPLa and
MyoG, respectively, were used to generate recombinant lentiviruses for
myoblast infection to establish cell lines. Vector expressing nonsilencing
shRNA (RHS4346) was used as a control. Briefly, the 293FT (Invitrogen,
Carlsbad, CA) cells were transfected with the lentiviral vector expressing
specific shRNAwith twohelper vectors, pMD2.G andpsPAX2, to produce
the lentivirus. C2C12 myoblasts were then infected with the virus at an
MOI (multiplicity of infection) of 10with Polybrene (8g/ml) to enhance
the virus transduction. The viral infection was monitored by following
GFP expression. The stable cell lines were established by selection with
puromycin (10 g/ml).
Immunostaining and immunoblotting. Cells on a glass coverslip
were briefly fixed using 4% paraformaldehyde and permeabilized using
phosphate-buffered saline containing 10% FBS and 0.2% Triton X-100.
The cells were then treated with a blocking solution, phosphate-buffered
saline with 5% BSA and 0.1% Triton X-100, before incubations with an-
tibodies were performed. The primary anti-myosin heavy chain (anti-
MHC) antibody (MF-20; Developmental Studies Hybridoma Bank) and
the secondary goat anti-mouse IgG antibody coupled with Alexa Fluor
594 (Invitrogen, Carlsbad, CA)were used.Nuclei were visualized byDAPI
(4=,6=diamidino-2-phenylindole) staining (Vectashield, Vector Laborato-
ries, Inc.), and images were acquired by fluorescence microscopy. Myo-
blast morphological differentiation images were taken using phase-
contrast microscopy. Protein samples for Western blot analysis were
extracted and separated as described previously (13). Antibodies against
PTPLa, MyoG, and p21 were from Bethyl Laboratory, Inc., Santa Cruz
Biotechnology, and Cell Signaling, respectively. Equivalent protein load-
ings were verified and normalized according to the intensities of GAPDH
(glyceraldehyde-3-phosphate dehydrogenase) blots.
QPCR analysis. Transcripts were quantified by quantitative PCR
(QPCR) analysis (Stratagene Mx3000p qPCR system) using the SYBR green
method with a MasterMix buffer system containing Taq polymerase (Strat-
agene) as described previously (39). Total RNAs was prepared by TRIzol
extraction (Gibco BRL). The forward/reverse PCR primers (5= to 3=) were
as follows: for PTPLa (NM_013935), CCGGGTGGTTGGTTCTTGCTA
TT/GCGGCAAGTGGTCGAGGAGA; forMyoG (NM_031189), TGGAG
CTGTATGAGACATCCC/TGGACAATGCTCAGGGGTCCC; for Acta-1
(NM_009606), AGACACCATGTGCGACGAAGA/TGCAGACCTTCGA
TGTAGCGGAT; for TnC (NM_009394), TTTGGGTGGTGGAGT
GCGGAGGAGA/GTCACAGAGCCCAAAGGAGCAGCCTT; for myh3
(NM_001099635), TGAAGAAGGAGCAGGACACCAG/CACTTGGAG
TTTATCCACCAGATCC; for myh8 (NM_177369), AACTGAGGAAGA
CCGCAAGAATG/AAGTAAACCCAGAGAGGCAAGTGACC; for MyoD
(NM_010866), GCAGGCTCTGCTGCGCGACC/TGCAGTCGATCTCT
CAAAGCACC; for Myf5 (NM_008656), TGCCATCCGCTACATTGAG
AG/CCGGGGTAGCAGGCTGTGAGTTG; and for Myf6 (NM_008657),
CTGCGCGAAAGGAGGAGACTAAAG/ATGGAAGAAAGGCGCTGAA
GACTG. GAPDH expression levels were used for QPCR normalization.
Expression levels were determined by the 2Ct threshold cycle method.
BrdU staining, FACS with propidium iodide (PI) staining, and
M-phase assessment. Cells were synchronized and then cultured in GM
for 12 h followed by BrdU (bromodeoxyuridine) treatment for 45 min
before harvesting. The anti-BrdU antibody and the corresponding second
antibodywere purchased from Invitrogen (Zymed’s BrdU kit). Single-cell
suspensions containing at least 1 106 synchronized cells grown in GM
were prepared for the cell cycle analyses by FACS (fluorescence-activated
cell sorting) using a FACSCalibur system (Becton Dickinson Biosciences,
San Diego, CA) (28). The data were processed using ModFit LTTM soft-
ware (Verity Software House, Inc., Topsham, ME) to determine cell pop-
ulations in the G0/G1, S, and G2/M phases. To further assess the cell pop-
ulation in M phase, the synchronized cells were cultured in a serum
restoration growthmedium for 0, 4 and 8 h. Cell nuclei were visualized by
DAPI staining. Five random images were taken using a 20 florescent
microscopy objective. Cells showing typical telophase morphology (dou-
ble nuclei) were counted as M phase positive. The percentage of M-phase
population was calculated by comparing the number ofM-phase-positive
cells to total nuclei.
Electrophoretic mobility shift assay (EMSA). The 32P-labeled 19- to
20-bp-long DNA duplexes containing the individual serum response ele-
ments (SREs) from the 5-kb region upstreamof the PTPLa genewere used
as probes, and the control SRE-positive probe was derived from a skeletal
-actin promoter containing one SRE (14).Mutant SRE probes were used
to validate the specificity of binding. The probes (5= to 3=) were as
follows: for SRE1, TTGTTCCTCCTATGGGGCT/AGCCCCATAGGAG
GAACAA; for SRE2, TAGCTCCTTCTCTGGGGACC/GGTCCCCAGAG
AAGGAGCTA; for SRE3, ACATCCATAAAAGGAAAGA/TCTTTCCTT
TTATGGATGT; and for the mutant SRE3, ACATAAATAAAAAAAAAG
A/TCTTTTTTTTTATTTATGT. Experiments examining the supershift
by the anti-SRF antibody and competition with unlabeled probe were
conducted to verify the SRF-DNA interaction as described previously
(59). Nuclear extracts were used for each experiment.
Luciferase assay. The 5-kb region upstream of the PTPLa gene con-
taining the SRE3 site was subcloned into pGL3-basic vector expressing a
luciferase reporter gene (Promega). A similar vector with the SRE3 mu-
tant was constructed as a mutant reporter vector. Generation of the SRF
expression vector and transient transfections were described previously
(14). The luciferase assay was conducted 36 h posttransfection. Lysis buf-
fer was purchased from Promega (E3971), and 20 of 60 l of the lysis
supernatant was used with aMonolight 3010 luminometer (Pharmingen)
for the measurement of luciferase activity. Each sample was measured
three times. All results were normalized to -galactosidase activity (MRX
Revelation; DYNEX Technologies).
Chromatin immunoprecipitation (ChIP) assay. The SRF expression
vector was transfected into C2C12 cells. After 36 h, cells were gently fixed
with formaldehyde and lysed by sonication. The specific SRF-DNA com-
plex was immunoprecipitated using anti-SRF antibody. The identity of
the DNA fragments isolated in the complex with SRF was determined by
PCR, and the final PCR products were then sequenced to confirm the
presence of the SRE motif.
Generation of skeletal- and cardiac-muscle-specific SRF knockout
mice. Constitative SRF knockout resulted in early embryonic lethality
due to several defects in mesoderm formation (4). To avoid the lethal-
ity and evaluate the PTPLa expression level under SRF-null condi-
tions, SRFloxp/loxp mice (a generous gift from Alfred Nordheim) were
bred with MHC-MerCreMer and MCK-Cre mice (Jackson Labora-
tory) to generate SRFloxp/loxp/Mer-CreMer and SRFloxp/loxp/MCK-Cre mice,
respectively. SRF deletion in cardiomyocytes was achieved by application
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of tamoxifen (20g/g of bodyweight; intraperitoneal injection for 4 days)
(57). All experiments with animals were approved by the Institutional
Animal Care and Use Committee of the Texas A&M Health Science
Center—Houston.
Statistical analysis. Data were expressed as means standard errors
of the means. In multiple comparisons, one-way analysis of variance
(ANOVA) was used followed by the Holm-Sidak method. In two-group
comparisons, a nonpaired t test was used (SigmaPlot, version 11.0). A
value of P 0.05 was considered significant.
RESULTS
PTPLa is highly expressed in cardiac and skeletal muscle. To
explore the biological functions of PTPLa,we evaluated the PTPLa
expression profile in six different adult mouse tissues. The highest
expression level of PTPLa mRNA was observed in the heart fol-
lowed by skeletal muscle (Fig. 1). The transcription level of PTPLa
was assessed by regular PCR (Fig. 1A) and quantified by QPCR
analysis (Fig. 1B). The PTPLa mRNA level in the heart was more
than 2-fold higher than in skeletalmuscle (Fig. 1B). PTPLamRNA
was undetectable in the rest of the tissues. A similar observation
was made for PTPLa protein expression assessed by Western blot
analysis (Fig. 1C). The PTPLa protein expression was detected in
bothmouse heart and skeletal muscle, with the highest level in the
heart (Fig. 1C). A trace PTPLa protein was detected in testis but
not in other tissues.
PTPLa is upregulated during myoblast differentiation, and
the differentiation is impaired in the presence of PTPLa defi-
ciency. Since PTPLa is highly expressed in cardiac and skeletal
muscles, we used the loss- and gain-of-function approaches to
focus on PTPLa’s role in skeletal myogenesis in C2C12myoblasts.
The PTPLa-deficient myoblast cell line was established by the use
of lentivirus-expressing PTPLa-specific shRNA. Themyoblast dif-
ferentiation was then induced in both the control (nonspecific-
shRNA-treatedmyoblasts) and PTPLa-deficient myoblast cells by
serum deprivation (differentiation medium [DM]), and the PT-
PLa transcript and protein levels were assessed by QPCR (Fig. 2A)
and Western blot analysis (Fig. 2B). We observed that the PTPLa
mRNA level gradually increased to the peak value at differentia-
tion day 3 in control myoblasts and then returned to the basic
level. The dynamic change in PTPLa expression during differen-
tiation was completely blocked in PTPLa-deficient myoblasts.
Typical myoblast differentiation morphology changes, with cell
elongation and alignment, cell fusion, andmyotube formation, were
observed in the wild-type and control myoblasts (Fig. 2C, left and
right panels, respectively). However, the myoblasts lacking PTPLa
failed to differentiate and retained the proliferating status (Fig. 2C,
middle panel). This result implied a potential role of PTPLa inmyo-
blast terminal differentiation andmyotube formation.
To determine whether PTPLa is essential for myogenesis, the
expression of several myogenic markers was monitored during
myoblast differentiation. Significant increases in transcription of
Acta-1 (skeletal -actin), TnC (troponin C), Myh3 (embryonic
skeletal myosin heavy chain 3), and Myh8 (perinatal skeletal
FIG 1 PTPLa tissue expression profile. (A) PTPLa expression levels in differ-
ent adult mouse tissues were assessed by RT-PCR. (B) QPCR (the data repre-
sent the averages of three measurements with means standard errors). (C)
Western blot analysis. The highest expression level of PTPLa was found in
heart followed by skeletal muscle. PTPLa expression was undetectable in the
rest of the tissues, except a trace of PTPLa protein was detected in testis tissue.
Hr, heart; Sk, skeletal muscle; Li, liver; Ts, testis; Si, small intestine; Ki, kidney;
GAPDH, glyceraldehyde-3-phosphate dehydrogenase. Samples in each tissue
category from four animals were used for QPCR analysis.
FIG 2 Upregulated PTPLa expression during myoblast differentiation and
impairedmyogenesis when PTPLa is lacking. (A)Myoblast differentiation was
induced by DM (differentiationmedium), and amarked transcript increase in
the PTPLa level was detected by aQPCR assay. The upregulated PTPLa expres-
sion was totally abolished in PTPLa-deficient myoblasts. The time point data
represent the averages of the results of threemeasurements (means standard
errors). (B) The change in PTPLa protein level was assessed by the Western
blot analysis. (C) The mutant myoblasts failed to differentiate, showed no
myotube formation, and retained the proliferating morphology changes. The
images were taken after 3 days of culture in DM. WT, wild type.
PTPLa and Myogenesis
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myosin heavy chain 8) were detected in the control myoblasts by
QPCR analysis, and the increases were impeded in the PTPLa-
deficient myoblasts (Fig. 3A). The myotube formation was ob-
served along with an induction of MHC (myosin heavy chain)
expression in the control myoblasts but not in the PTPLa-
deficient myoblasts (Fig. 3B). The Western blot result for MHC
protein expression was consistent with the immunohistochemis-
try observation (Fig. 3C), showing a lack of MHC protein induc-
tion in PTPLa-deficient myoblasts. Together, these data indicated
that myogenesis was impaired by a loss of PTPLa in C2C12 myo-
blasts.
PTPLa regulates myogenesis throughMyoG. Skeletal muscle
differentiation is tightly regulated by basic helix-loop-helix myo-
genic regulatory factors (MRFs) MyoD, Myf5, MyoG, and MRF4
(1–3, 6, 9). These factors function as master regulators in skeletal
muscle development. To evaluate their roles in PTPLa-mediated
myoblast differentiation, we analyzed expression of these four
skeletal-muscle-specific regulatory factors by QPCR during myo-
blast differentiation. A marked increase in MyoG mRNA levels
was observed in control myoblasts; however, the deficiency of
PTPLa completely impeded the MyoG increase (Fig. 4A). The
repressed MyoG protein expression in the mutant myoblasts was
observed by the Western blot analysis (Fig. 4B). No significant
differences between the control and PTPLa-deficientmyoblasts in
MyoD, Myf5, and MRF4 expression levels were found (Fig. 4A).
This result implicated MyoG as a potential myogenic regulator in
PTPLa-mediated myoblast differentiation.
To define the role of MyoG in PTPLa-mediated myoblast dif-
ferentiation, a myoblast cell line lacking MyoG expression was
generated. Two cell lines, the PTPLa-deficient and MyoG-
deficient myoblasts, were used to test the hypothesis that PTPLa-
mediated myoblast differentiation was induced through MyoG
regulation. The plasmids expressing PTPLa andMyoGwere trans-
fected into the two mutant myoblasts, and the cell morphology
changes, as well as levels of myogenic markers Acta-1 and MHC,
were assessed (Fig. 5). After transfection with the PTPLa expres-
sion vector, PTPLa-deficient myoblasts resumed the differentia-
tionmorphology changes, with cell elongation and alignment and
myotube formation. The differentiation resumptionwas observed
in PTPLa-deficient myoblasts transfected with MyoG expression
vector as well (Fig. 5A, upper panels). In theMyoG-deficientmyo-
blasts, however, the cells resumed differentiation morphology
changes only after MyoG expression vector transfection and not
FIG 3 PTPLa-deficient myoblasts failed to express myogenic markers. (A)
The induction of Acta-1, Myh3, TnC, and Myh8 transcripts was evaluated by
QPCR, and upregulation of these myogenic markers was abolished in PTPLa-
deficientmyoblasts. The time point data represent the averages of the results of
three measurements (means  standard errors). (B) MHC expression and
myotube formation were observed in control myoblasts but not in the mutant
myoblasts by immunostaining. (C) The level of MHC protein was assessed by
Western blot analysis, and no MHC protein was detected in the mutant
myoblasts.
FIG 4 Impaired MyoG expression in PTPLa-deficient myoblasts. Four major
skeletal myogenic regulatory factors were assessed during myoblast differenti-
ation by QPCR (A), and no upregulation ofMyoG transcripts and protein was
observed in the mutant myoblasts (A and B). The time point data in panel A
represent the averages of the results of threemeasurements (means standard
errors).
Lin et al.
300 mcb.asm.org Molecular and Cellular Biology
 o
n
 Septem
ber 12, 2018 by guest
http://m
cb.asm
.org/
D
ow
nloaded from
 
after PTPLa expression vector transfection (Fig. 5A, lower panels),
suggesting that MyoG may function downstream of PTPLa. This
suggestion was supported by the QPCR andWestern blot evalua-
tion of expression levels for myogenic markers Acta-1 and MHC.
The inductions of Acta-1 transcript and MHC protein were im-
peded in PTPLa-deficient as well as inMyoG-deficient myoblasts.
Reintroduction of PTPLa or MyoG rescued Acta-1 and MHC
expression in PTPLa-deficient myoblasts. However, in MyoG-
deficient myoblasts, Acta-1 and MHC expression was rescued
only by MyoG transfection and not by PTPLa transfection. To-
gether, these data demonstrated that, as a transcriptional regulator
downstream of PTPLa, MyoG was responsible for PTPLa-
mediated myoblast differentiation.
Myoblast proliferationwas impeded by PTPLa deficiency. In
the study of PTPLa’s role in myogenesis, we observed that myo-
blasts lacking PTPLa grew much slower in the growth medium
than controlmyoblasts. To quantify the growth retardation, equal
amounts of PTPLa-deficient and controlmyoblasts were synchro-
nized and cultured in the growthmedium to assess the cell growth
rate differences. As shown in Fig. 6A, there were significantly
smaller amounts of cells in the PTPLa-deficient group than in the
control group. This gap in cell numbers was augmented at later
times as cells grew exponentially. Meanwhile, the impeded cell
proliferation in PTPLa-deficient myoblasts was confirmed by
BrdU pulse-labeling at the 12-h time point. The number of BrdU-
positive cells in the PTPLa-deficient group was about half of the
control level, suggesting a proliferation defect in PTPLa-deficient
myoblasts (Fig. 6B and C).
PTPLa knockdown resulted in S-phase arrest and compro-
mised G2/M transition inmyoblasts. To study themechanism of
FIG5 Impairedmyogenesis in PTPLa-deficientmyoblasts was rescued byMyoG. (A)Morphological changes of PTPLa-deficient andMyoG-deficientmyoblasts
after introduction of PTPLa andMyoG. The disruptedmyotube formation observed in PTPLamutant myoblasts was rescued by reintroducingMyoG or PTPLa
(top panels). The impairedmyogenesis inMyoG-deficientmyoblasts was rescued only by reintroducingMyoG but not PTPLa (lower panels). (B)QPCR analysis
of myogenic marker Acta-1 transcript levels in PTPLa andMyoGmutant myoblasts after introduction of PTPLa andMyoG. , P 0.01 compared to h 0 in DM.
The time point data represent the averages of the results of three measurements (means standard errors). (C) Western blot analysis of the protein expression
levels for another myogenic marker, MHC, in PTPLa and MyoG mutant myoblasts after introduction of PTPLa and MyoG.
PTPLa and Myogenesis
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myoblast proliferation regulated by PTPLa, we evaluated the time
dependence of the PTPLa effect on cell cycle progression. Syn-
chronized (by low serum) myoblasts under subconfluent culture
conditionswere labeledwith PI and analyzed byDNAflow cytom-
etry (Fig. 7). As expected, the cell-cycling phases showed no sig-
nificant differences between the mutant and control myoblasts at
the 0 h time point (immediately after cell synchronization). Sig-
nificant increases in S-phase populations of PTPLa-deficientmyo-
blasts were observed at the 4 h (42.75%) and 8 h (36.26%) time
points compared to the control myoblasts (34.70% and 19.99%,
respectively). However, cell populations of the mutant myoblasts
in the G2/M phase became smaller (19.60% and 16.81% at the 4 h
and 8 h time points, respectively) compared to the control myo-
blasts (36.73% and 29.84%, respectively), indicating a compro-
mised G2/M progression in PTPLa-deficient myoblasts. To fur-
ther verify the abnormal G2/M progression in the mutant
myoblasts, cells in theM phase were quantified. Themutantmyo-
blasts lost dynamic changes, with only half of the control level’s
cell populations in M phase (Fig. 8A).
Cyclin D1–cyclin-dependent kinase 4/CDK6 (CDK4/6) and
cyclin E2-CDK2 are major regulatory complexes that regulate the
checkpoint in the G0/G1- to S-phase transition (37, 44). To inves-
tigate whether the upregulation of these complexes occurred in
PTPLa-deficient myoblasts, immunoblot analysis of individual
cyclins and CDKs was performed. As indicated in Fig. 8B and C,
the cyclin D1, CDK4, CDK6, and cyclin E2 expression levels were
markedly increased in the mutant myoblasts compared to the
control cells. This suggested that the PTPLa expression level was
critical for G1/S phase transition and that the PTPLa deficiency
facilitated the G1/S-phase transition. The PTPLa-deficient myo-
blasts also displayed an abnormal G2/M progression. Since CDK1
is a key regulator of the G2-to-M-phase transition and the regula-
tion of CDK1 activity involves phosphorylation and dephosphor-
ylation of the kinase, the phospho-CDK1 level was assessed by
Western blot analysis. As indicated in Fig. 8D, hyperphosphory-
lation of CDK1 was detected in the mutant myoblasts along with
the upregulation of Myt1, indicating that an inactive CDK1
may contribute to the restrained G2-to-M transition. Enhanced
activity of cyclin/CDK could deregulate DNA replication and
cause DNA damage leading to cell death (7), which may poten-
tially contribute to the PTPLa mutant cell growth retardation.
To rule out this possibility, we conducted terminal deoxy-
nucleotidyltransferase-mediated dUTP-biotin nick end labeling
(TUNEL) and caspase activity assays, which displayed no signifi-
cant increase in cell death in the mutant myoblasts (data not
shown). Finally, we demonstrated the mutant cell cycle defects by
double-thymidine-synchronization treatment. Consistent with
the low-serum synchronization result, a larger population of cells
in the S phase, along with the smaller numbers of cells in the G2/M
phase, was observed in the mutant myoblasts after 4-h and 8-h
release from thymidine blocks compared to the wild-type con-
trol myoblast results (Fig. 9A). In line with the higher percent-
age of cells in the S phase, the mutant myoblasts displayed
higher BrdU-positive cell numbers in comparison with the
control cells (Fig. 9B). Meanwhile, the expression of p21 pro-
tein, a cyclin-dependent kinase inhibitor, was increased in the
mutant myoblasts at the 0 and 4 h time points after the cell release
from thymidine blocks, indicating a potentialmechanismand fur-
ther supporting the finding regarding the cell cycle arrest pheno-
type in the mutant cells (Fig. 9C). Taken together, these data sug-
gested that the upregulation of cyclinD1 and cyclin E2 complexes,
alongwith the inactivatedCDK1 and upregulated p21,might have
been responsible for the PTPLa deficiency-mediated S-phase ar-
rest that contributed to the impeded cell growth.
PTPLa is a direct SRF gene target. Serum response factor is
essential for skeletal- as well as cardiac- and smooth-muscle gene
expression (40, 41, 49).Mice with an SRF deletion in skeletalmus-
cle experienced a severe deficiency in skeletal muscle growth and
improper maturation (40). Using computational biology ap-
proaches (Genomatix), we analyzed the 5-kb sequence upstream
of the PTPLa gene and identified three putative SRF binding sites:
SRE1 (serum response element 1), SRE2, and SRE3 (Fig. 10A).
The SRE consensus sequence is CC(A/T)6GG, with an AT-rich
core. To determine whether SRF binds to the identified SREs, an
EMSA was performed. Three 32P-labeled DNA duplexes contain-
ing SRE1, SRE2, and SRE3were used as probes (14). A strong band
shift was observed only when the SRE3 probe was incubated with
the nuclear extract, and no shift was observed for SRE1 or SRE2
probes (Fig. 10B). This suggested that SRFmay bind to the PTPLa
promoter via the SRE3. To verify the SRF-SRE3 interaction, a
comprehensive EMSA was conducted (Fig. 10C). As expected, a
band shift was displayed with the addition of the wild-type SRE3
and nuclear extract (lane 3), while no SRF binding to the mutant
SRE3 probe was observed, thus validating the binding specificity
(lane 4). A supershift band was obtained by adding an anti-SRF
antibody (lane 5), confirming the SRF-SRE3 interaction. Finally,
an excess of unlabeled wild-type SRE3 probe was included in the
SRF-SRE3 binding reaction, which resulted in the abolishment of
FIG 6 Myoblast proliferation was impeded by PTPLa deficiency. Cells were
synchronized and cultured in the growthmedium to assess the cell growth rate.
(A and B) A retarded growth rate was observed (A), with fewer BrdU-stained
cells in PTPLa mutant myoblasts (B). Brown, positive BrdU staining. Arrows
indicate representative BrdU-positive cells. The panel A time point data rep-
resent the averages of the results of three measurements. (C) Quantitative
analysis of BrdU staining. BrdU-positive cells were quantified from nine im-
ages taken from three slides at the 12-h time point. Data represent means 
standard errors. , P  0.01 compared to 0 h time point; , P  0.01 com-
pared to control.
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the SRF-SRE3 band shift (lane 6). This experiment confirmed that
SRF is able to bind the SREmotif in the PTPLa promoter region in
vitro.
To investigate whether SRF interacts with the PTPLa promoter
region in vivo, a ChIP assay was performed (66). The specific SRF-
DNA complex was immunoprecipitated using an anti-SRF anti-
body. Sequencing analysis showed that the DNA fragments iso-
lated in the complex contained part of the PTPLa 5=-upstream
sequence with the SRE3 site (Fig. 10D). Thus, the in vivo interac-
tion of SRF with the SRE3 site in the PTPLa promoter region was
confirmed.
To explore the functional significance of SRE3, a 5-kb-long
duplex of the PTPLa 5=-upstream sequence containing the SRE3
site was subcloned into a luciferase reporter vector. The chimeric
vector can express luciferase as a reporter under PTPLa promoter
control. The effect of SRF on luciferase expression can be detected
from the changes in luciferase activity. We cotransfected the SRF-
expressing vector, and the introduction of SRF increased lucifer-
ase activity more than 5-fold compared to the baseline control
without SRF (Fig. 10E). In a parallel experiment, the proactive
effect of SRF on the PTPLa promoter was completely abolished by
the mutation of SRF binding site SRE3 in the PTPLa promoter.
This result strongly suggests that the PTPLa is regulated by SRF.
To further demonstrate that PTPLa is one of the SRF direct-
target genes, we evaluated PTPLa expression in skeletal muscle
from skeletal-muscle-specific SRF deletion mice by the use of a
conditional SRF allele harboring loxP sites (SRFloxp/loxp) flank-
ing SRF exon 1 (64). Skeletal-muscle-specific SRF deletion was
achieved by using aMCK-Cre transgene that has been shown to be
activated in skeletal-muscle cells to delete the SRFloxp/loxp allele
(12, 40). Skeletal muscle extracted from postnatal day 2 mice was
assessed. Based on the Western blot analysis, we estimate that the
MCRK-Cre transgene directed deletion of at least 90% of SRF in
skeletal muscle (Fig. 11A). PTPLa protein and mRNA levels
were then evaluated by Western blot analysis, regular reverse
transcription-PCR (RT-PCR), and QPCR (Fig. 11A, B, and C).
The results showed marked decreases in PTPLa protein and
mRNA expression levels in mutant animal skeletal muscle com-
pared to wild-type animals, suggesting PTPLa as one of SRF reg-
ulatory genes.
Most transcription regulatory mechanisms are highly con-
served. Because PTPLa is highly expressed in both skeletal muscle
and heart tissues, we asked whether the SRF regulation of PTPLa
expression was also active in the heart. An inducible MHC-
MerCre transgene was used to delete the SRFloxp/loxp allele (57),
and based on theWestern blot analysis, the SRFprotein level in the
FIG 7 PTPLa knockdown resulted in S-phase arrest in myoblasts. (A) Flow cytometry analysis revealed the impeded S phase and attenuated G2/M phase in
PTPLa-deficientmyoblasts. (B) Cell population distribution in cell cycle. The h 0, 4, and 8 time points indicate the periods of time duringwhich the synchronized
cells were cultured in the serum restoration growth medium. The data represent the averages of the results of experiments repeated three times with means
standard errors. , P 0.01 compared to control (Cont).
PTPLa and Myogenesis
January 2012 Volume 32 Number 2 mcb.asm.org 303
 o
n
 Septem
ber 12, 2018 by guest
http://m
cb.asm
.org/
D
ow
nloaded from
 
heart was reduced by more than 90% (Fig. 11D). Along with the
decrease in SRF expression, significant reductions in PTPLa pro-
tein and mRNA levels were also observed (Fig. 11D, E, and F),
whichwas consistent with the observations of skeletalmuscle. The
result revealed a conserved regulatory mechanism in PTPLa gene
expression.
DISCUSSION
Emerging evidence reveals that protein tyrosine phosphatases are
involved in regulation of skeletal-muscle myogenesis (18, 22–24,
27, 32–34, 42, 60). For example, mutations in myotubularin 1, a
PTPase encoded by the MTM1 (myotubular myopathy) gene in
humans, is responsible for X-linked centronuclear myopathy in
humans and canines (8, 35, 36). Besides the typical PTPases, a new
family of protein tyrosine phosphatase-like (PTPL) genes has been
identified (26, 62). PTPL proteins have a conserved PTPase cata-
lytic motif, (I/V)HCXXGXXP(S/T), except for the substitution of
proline (P) for arginine (R). The biological consequence of the
variation is unclear. One recent study in PTPLb, a member of the
PTPL family, showed that the restoration of arginine had a mini-
mal effect on PTPase activity (62). Further enzymatic analysis of
PTPL is necessary to understand its biochemical characteristics.
Previously, high expression levels of PTPLa mRNA were de-
FIG 8 Cell cycle checkpoint dysregulation in PTPLa-deficient myoblasts. (A)
A dynamic change in the M-phase cell population was lost in the mutant
myoblasts. The h 0, 4, and 8 time points indicate the periods of time during
which the synchronized cells were cultured in the serum restoration growth
medium. (B and C) Western blots (left panels) showed upregulation of cyclin
D1-CDK4/6 and cyclin E2-CDK2 regulatory complexes in the mutant myo-
blasts. (D)HyperphosphorylatedCDK1, alongwith upregulation ofMyt1, was
detected in the mutant myoblasts byWestern blot analysis (left panels). (B, C,
and D) The right panels display the results of blot densitometry analyses de-
rived from the associated blots shown in the corresponding right panels. Data
represent the averages of the results of three measurements from three re-
peated experiments, with normalization using GAPDH. , P 0.01 compared
to control. Bar, 100 m. a.u., arbitrary units.
FIG 9 The PTPLa deficiency-mediated cell cycling defect was assessed in cells
with double-thymidine synchronizations. (A) Impeded S phase and attenu-
ated G2/M phase in PTPLa-deficient myoblasts were detected by flow cytom-
etry analysis after double-thymidine blocks followed by 4- and 8-h blockage
releases, respectively. The data represent the averages of the results of three
repeated experiments. , P 0.05 compared to the control (Ctrl) results from
the indicated time points. (B) The number of BrdU-positive cells (pink) was
assessed at the 4-h time point after the thymidine blockage release and was
higher in PTPLa-deficient myoblasts than in the control cells. BrdU-positive
cells were quantified from nine images taken from three slides (right panel).
, P  0.01. (C) Western blot analysis showed upregulated p21 protein ex-
pression in PTPLa-deficient myoblasts (mutant).
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tected in both human and mouse heart- and skeletal-muscle tis-
sues (38, 61). In this study, we found that PTPLa protein was
almost exclusively expressed in striated muscles, with the highest
protein level detected in mouse heart followed by skeletal muscle,
implying its potential role in these tissues. Genetic linkage studies
from two independent groups identified PTPLa genemutations in
patients suffering fromARVD (31, 38), although a direct relation-
ship betweenmutations and disease was not established due to the
limitations in human study. Genetically manipulated mouse
models such as mutant PTPLa knockin or PTPLa knockout ani-
malmodels would help define the pathogenic consequences of the
presence of mutant PTPLa in heart tissue. Intriguingly, a “natural
knockout” PTPLa animal that was due to a SINE (short inter-
spersed repeat element) insertion in the exon of the PTPLa gene
was reported in a group of Labrador retrievers. The SINE insertion
led to either premature stop or truncated frameshift codons that
resulted in PTPLa functional deficiency. Themutant dogs suffered
from congenital myopathy with severe hypotonia. Histology anal-
ysis revealed centronuclear myopathy along with type 1 fiber at-
rophy and a type 2 fiber deficiency in skeletal muscle, which
closely mimics human autosomal dominant and recessive forms
of centronuclear myopathy (52).
FIG 10 Analysis of PTPLa gene promoter region. (A) Three putative SRF binding sites (SRE1 to SRE3) in the PTPLa gene promoter region were suggested by
bioinformatics predictions. (B) Only SRE3 showed interaction with SRF by EMSA. (C) A comprehensive EMSA further demonstrated specific interaction
between SRF and the SRE3. (D) A ChIP assay verified their interaction in vivo. (E) Addition of SRF activated luciferase activity driven by the PTPLa promoter
(empty bars), and mutation of the SRE3 abolished the SRF-mediated reporter activity (gray bars). The data in panel E represent the averages of the results of six
measurements, with normalization to the baseline level in the absence of SRF (means standard errors). , P 0.01.
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While all of those previous studies provided strong evidence of
PTPLa’s function inmyogenesis, the underlyingmolecular mech-
anism remained unknown. In this study, we identified MyoG as a
downstream target of PTPLa. Skeletal myogenesis is tightly or-
chestrated by members of the MRF family, including MyoD,
Myf5, MyoG, and MRF4. MyoD and Myf5 are required for the
commitment of proliferating somitic cells to the myogenic lin-
eage, whereas MyoG is required for committed cells (myoblasts)
to differentiate into mature myocytes and myotube formation.
Targeted disruption of the MyoG gene in mice resulted in perina-
tal lethality with severe defects in skeletal muscle (25, 48). C2C12
myoblasts proliferate under high-serum conditions and sponta-
neously differentiate upon serum withdrawal. We observed dra-
matic increases in MyoD, Myf5, and MyoG expression in C2C12
cells after serumwithdrawal; however, the PTPLa deficiency com-
pletely blocked the responsive increase in MyoG expression but
not in MyoD and Myf5 expression. In parallel with the lack of
increase in MyoG expression, the myoblasts lacking PTPLa failed
to differentiate and form myotubes. The cells retained the prolif-
erating status even in the serum-free differentiation medium. To
understand the relationship between the PTPLa and MyoG, we
generated a MyoG-deficient myoblast cell line that (as expected)
showed impaired differentiation. By individual rescue experi-
ments, we demonstrated that the introduction of MyoG was suf-
ficient to restore myoblast differentiation in PTPLa-deficient cells
and inMyoG-deficient cells. However, introduction of PTPLa res-
cued the cell differentiation only in PTPLa-deficient cells and not
in MyoG-deficient cells. This suggested that PTPLa regulated
myoblast differentiation at least partially throughMyoG. The next
intriguing issue is how PTPLa regulatesMyoG. Several early stud-
ies demonstrated that MyoG is positively regulated by another
essential muscle transcription factor, MEF2 (myocyte enhancer
factor 2) (19, 29, 56).We found thatMEF2 activity was attenuated
in the mutant myoblasts, suggesting possible signaling from
PTPLa through MEF2 to regulate MyoG (data not shown).
In this study, we also discovered lower cell growth and DNA
synthesis rates in PTPLa-deficient myoblasts. Flow cytometry and
immunoblot analyses revealed the S-phase arrest in the mutant
cells along with the upregulation of cyclin D and cyclin E com-
plexes. In general, the active complex of cyclinD/CDK4 targets the
retinoblastoma protein (pRb) for phosphorylation, allowing the
release of E2F transcription factors that activate the G1/S-phase
gene expression (43). Activation of cyclin D/CDK4/6 results in
phosphorylation of pRb, which reduces the activity of p21 Waf1/
Cip1 and p27 Kip1, allowing subsequent activation of cyclin
E/CDK2 (37, 44). Cyclin E/CDK2 further phosphorylates pRb to
facilitate the progression into the S phase (21). Therefore, the
upregulated cyclin D/CDK4 and cyclin E/CDK2 observed in
PTPLa-defective myoblasts enhanced cell entry into the S phase.
Meanwhile, the flow cytometry analysis and low growth rate indi-
cated that PTPLa-defective myoblasts failed to divide and to com-
plete the G2-to-M transition. To reveal a possible mechanism, we
analyzed the key regulator in the G2/M transition, CDK1 (cyclin-
dependent kinase 1), encoded by the cdc2 gene in humans. It is
well known that dephosphorylation of CDK1 tyrosine-15 and
threonine-14 sites activates the kinase and advances cells into mi-
tosis (5, 50). Phosphorylation of CDK1 by Myt1 and Wee1 ki-
nases, however, keeps the CDK1 complex in an inactive state and
prevents cells from undergoing the G2/M transition (45, 63). In
PTPLa-deficient myoblasts, hyperphosphorylated CDK1, along
with upregulation of Myt1, was observed. Although we do not
know whether CDK1 is a direct dephosphorylation target of
PTPLa, the impaired G2/M transition due to PTPLa deficiency
strongly implies that this is the case. Furthermore, with the double-
thymidine treatments, upregulated p21 expression was observed,
suggesting a potential mechanistic role of p21 in PTPLa-mediated
cell proliferation regulation. Taking these results together, we be-
lieve that the enhancedG1-to-S entrymediated by upregulation of
the cyclin D/CDK4 and cyclin E/CDK2 complexes, along with a
compromisedG2/M transition due to the repressed CDK1 activity
and upregulated p21, results in cell cycle arrest, which eventually
contributes to retarded cell growth.
It is important to realize that, from the biological process point
of view, cell proliferation and differentiation are “mutually exclu-
sive” in the sense that differentiation starts when proliferation
ceases. However, this does not mean that when one process is
impaired the other is necessarily enhanced. In this study, we found
that both cell proliferation and differentiation were impaired by
PTPLa deficiency through different mechanisms, one operating
through cell cycle checkpoint regulation and the other operating
throughMyoG to regulate differentiation, suggesting that the reg-
ulation of myogenesis is complicated, as demonstrated by many
earlier studies (40, 58).
Finally, we studied the transcriptional regulation of the PTPLa
gene and identified PTPLa as a new target gene for SRF, an essen-
tial transcription factor for skeletal-, cardiac-, and smooth-muscle
FIG 11 Downregulation of PTPLa expression in SRF-null skeletal and cardiac
muscle. (A to C) Skeletal muscle. (D to F)Myocardium. (A and D) Significant
decreases in the SRF protein expression were achieved in skeletal muscle- and
cardiac-muscle-specific SRF knockout (KO) animals. In parallel with the de-
cline in the SRF expression, repressed PTPLa transcription and protein expres-
sion were also detected in the skeletal and cardiac tissues, respectively. (B and
E) RT-PCR assay. (C and F) QPCR assay. Data are from four measurements
(means standard errors).
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development. A previous study demonstrated that mouse skeletal
muscle lacking SRF expression showed severe hypoplasia and
failed to grow (40). SRF directly bound to aDNA sequence known
as the serum response element and served as a platform to recruit
other muscle regulatory proteins in order to regulate contractile
protein gene expression (15, 40, 46, 49, 51).We found that PTPLa
regulation by SRFwas conserved in both skeletal and cardiacmus-
cle. In mice, the lack of SRF expression in skeletal muscle led to
significant decreases in PTPLa transcript and protein expression,
which is similar to the phenotype observed inmousemyocardium
lacking SRF expression. These results have provided in vitro and in
vivo evidence that SRF transcriptionally regulates the PTPLa gene.
Given the fact that SRF functions as amuscle “myogenic driver,” it
makes sense that PTPLamight be another new downstream target
of SRF and that it participates in muscle development.
In summary, the present study defined a promyogenic role of
PTPLa, revealed the underlying molecular mechanisms of PTPLa
in myoblast proliferation and differentiation, and demonstrated
PTPLa gene transcriptional regulation by SRF.
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Correction for Lin et al., “Protein
Tyrosine Phosphatase-Like A Regulates
Myoblast Proliferation and Differentiation
through MyoG and the Cell Cycling
Signaling Pathway”
Xi Lin,a Xiangsheng Yang,a Qi Li,b Yanlin Ma,b Shuang Cui,c Dacheng He,c
Xia Lin,d Robert J. Schwartz,e and Jiang Changa,b
Texas A&M Health Science Center, Institute of Biosciences and Technology, Houston, Texas, USAa; Hainan
Provincial Key Laboratory for Human Reproductive Medicine and Genetic Research, Affiliated Hospital of
Hainan Medical College, Hainan, Chinab; Beijing Normal University, Beijing, Chinac; Surgery/General Surgery
Division, Baylor College of Medicine, Houston, Texas, USAd; Biology and Biochemistry Department, University
of Houston, Houston, Texas, USAe
Volume 32, no. 2, p. 297–308, 2012, https://doi.org/10.1128/MCB.05484-11. Page
299, Fig. 2C: The WT panel was accidently chosen from the control group. The corrected
panel should appear as shown below.
Page 304, Fig. 8D: The GAPDH panel is erroneous. The corrected panel should
appear as shown below.
Citation Lin X, Yang X, Li Q, Ma Y, Cui S, He D,
Lin X, Schwartz RJ, Chang J. 2017. Correction
for Lin et al., “Protein tyrosine phosphatase-
like A regulates myoblast proliferation and
differentiation through MyoG and the cell
cycling signaling pathway.” Mol Cell Biol 37:
e00236-17. https://doi.org/10.1128/MCB
.00236-17.
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